美罗华和Zevalin治疗非霍奇金淋巴瘤临床研究
Rituximab and Zevalin in Treatment of Non-Hodgkin's B-Cell Lymphoma
摘要
美罗华单克隆抗体具有高度特异性,毒副作用小,是近年来淋巴瘤治疗上的突破性进展。临床可用于各种B细胞NHL的一线或二线治疗,可单独应用,亦可与化疗药物联合应用以提高疗效。Zevalin为90Y标记的鼠抗CD20单抗,于2002年通过FDA批准。可用于治疗美罗华治疗无效或复发的NHL患者,有效率仍可高达54％。
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
2004年第1期64-66,共3页
Chinese Journal of Cancer Biotherapy
参考文献26
-
1McLaughlin P, Gfillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program[J]. J Clin Oncol, 1998, 16(8) : 2825-2833.
-
2Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden : Clinical and molecular evaluation[ J]. Blood, 2001, 97 : 101-106.
-
3Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma [ J]. J Clin Oncol, 2002, 20(20) : 4261-4267.
-
4Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase Ⅱ study[ J ].Blood, 1998, 92(6) : 1927-1932.
-
5Foran JM, Rohatiner AZ, Cunningham D, et al. European phase Ⅱ study of rituximab (chimeric anti-CD20 monoclonal antibody)for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma[ J]. J Clin Oncol, 2000, 18(2) : 317-324.
-
6Emmanouilides C, Jazirehi AR, Bonavida B ,et al. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine and vinorelbine [ J ].Cancer Biother Radiopharm, 2002, 17 (6) : 621-630.
-
7Czuezman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma [J]. Semin Oncol, 2002, 29(2 Suppl 6) : 11-17.
-
8Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346(4):235 -242.
-
9Micallef IN, Kirk A, Norton A, et al. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [ J ]. Blood,1999, 93(7): 2427-2428.
-
10Witzig TE, White CA, Wiseman GA, et al. Phase Ⅰ / Ⅱ trial of IDEC-Y2B8 adioimmunotherapy for treatment of relapsed or refractory CD20( + ) B-cell non-Hodgkin's lymphoma[J]. J Clin Oncol, 1999, 17: 3793-3803.
-
1使用ZevaLin后再用美罗华可治疗非何杰金淋巴瘤[J].中华医学信息导报,2002,17(13):14-14.
-
2申景平.向恶性肿瘤开炮[J].中国科教创新导刊,2002,0(3):4-6.
-
3王建国,江丽君.抗体治疗非何杰金病[J].生物制品快讯,2003(6):19-20.
-
4Zevalin关键词：滤泡淋巴瘤[J].中国处方药,2008(3):20-20.
-
5周亚南,陈子兴,张旭辉,陶瑞芳,邵景章,张日,吴德沛.抗CD20单抗联合CHOP方案治疗B细胞性非霍奇金淋巴瘤[J].苏州大学学报（医学版）,2008,28(6):953-955. 被引量：1
-
6张军一,罗荣城.非霍奇金B细胞淋巴瘤的放射免疫治疗进展[J].解放军医学杂志,2003,28(2):186-187. 被引量：1
-
7张爽,王杨,孙雪飞.Zevalin治疗弥漫性大B细胞淋巴瘤ⅣB期1例[J].吉林大学学报（医学版）,2007,33(2):358-358.
-
8抗肿瘤药[J].国外药讯,2008(2):19-21.
-
9化疗药物-氟达拉滨（F1udarabine，F-ara-A，福达华）[J].中国处方药,2005(5):18-22.
-
10孟凡义,扶云碧.白血病细胞表面分子抗原的靶向治疗[J].中华医学杂志,2005,85(7):441-443. 被引量：2
